Research ExplorerPublicationsTP53 mutation is frequently associated with CTNNB1 mutation ...

TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.

Standard

TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. / Pfaff, Elke; Remke, Marc; Sturm, Dominik; Benner, Axel; Witt, Hendrik; Till, Milde; von Bueren, André; André, O; Wittmann, Andrea; Schöttler, Anna; Jorch, Norbert; Graf, Norbert; Kulozik, Andreas E; Witt, Olaf; Scheurlen, Wolfram; Rutkowski, Stefan; Rutkowski, Stefan; Taylor, Michael D; Tabori, Uri; Lichter, Peter; Korshunov, Andrey; Pfister, Stefan M.

In: J CLIN ONCOL, Vol. 28, No. 35, 35, 2010, p. 5188-5196.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Pfaff, E, Remke, M, Sturm, D, Benner, A, Witt, H, Till, M, von Bueren, A, André, O, Wittmann, A, Schöttler, A, Jorch, N, Graf, N, Kulozik, AE, Witt, O, Scheurlen, W, Rutkowski, S, Rutkowski, S, Taylor, MD, Tabori, U, Lichter, P, Korshunov, A & Pfister, SM 2010, 'TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.', J CLIN ONCOL, vol. 28, no. 35, 35, pp. 5188-5196. <http://www.ncbi.nlm.nih.gov/pubmed/21060032?dopt=Citation>

APA

Pfaff, E., Remke, M., Sturm, D., Benner, A., Witt, H., Till, M., von Bueren, A., André, O., Wittmann, A., Schöttler, A., Jorch, N., Graf, N., Kulozik, A. E., Witt, O., Scheurlen, W., Rutkowski, S., Rutkowski, S., Taylor, M. D., Tabori, U., ... Pfister, S. M. (2010). TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J CLIN ONCOL, 28(35), 5188-5196. [35]. http://www.ncbi.nlm.nih.gov/pubmed/21060032?dopt=Citation

Vancouver

Pfaff E, Remke M, Sturm D, Benner A, Witt H, Till M et al. TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma. J CLIN ONCOL. 2010;28(35):5188-5196. 35.

Bibtex

@article{f391dbff8059447996d4cda1ffc7ba89,
title = "TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.",
abstract = "The role of TP53 mutations in the tumorigenesis of sporadic medulloblastoma (MB) and the value of TP53 mutation status as a prognostic marker are not yet definitely elucidated. A recent report identified TP53 mutations in MB as an adverse prognostic marker. Hence, the current study was conducted to validate the prognostic role of TP53 mutation in MB and to understand its contribution to tumorigenesis.",
author = "Elke Pfaff and Marc Remke and Dominik Sturm and Axel Benner and Hendrik Witt and Milde Till and {von Bueren}, Andr{\'e} and O Andr{\'e} and Andrea Wittmann and Anna Sch{\"o}ttler and Norbert Jorch and Norbert Graf and Kulozik, {Andreas E} and Olaf Witt and Wolfram Scheurlen and Stefan Rutkowski and Stefan Rutkowski and Taylor, {Michael D} and Uri Tabori and Peter Lichter and Andrey Korshunov and Pfister, {Stefan M}",
year = "2010",
language = "Deutsch",
volume = "28",
pages = "5188--5196",
journal = "J CLIN ONCOL",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "35",

}

RIS

TY - JOUR

T1 - TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.

AU - Pfaff, Elke

AU - Remke, Marc

AU - Sturm, Dominik

AU - Benner, Axel

AU - Witt, Hendrik

AU - Till, Milde

AU - von Bueren, André

AU - André, O

AU - Wittmann, Andrea

AU - Schöttler, Anna

AU - Jorch, Norbert

AU - Graf, Norbert

AU - Kulozik, Andreas E

AU - Witt, Olaf

AU - Scheurlen, Wolfram

AU - Rutkowski, Stefan

AU - Rutkowski, Stefan

AU - Taylor, Michael D

AU - Tabori, Uri

AU - Lichter, Peter

AU - Korshunov, Andrey

AU - Pfister, Stefan M

PY - 2010

Y1 - 2010

N2 - The role of TP53 mutations in the tumorigenesis of sporadic medulloblastoma (MB) and the value of TP53 mutation status as a prognostic marker are not yet definitely elucidated. A recent report identified TP53 mutations in MB as an adverse prognostic marker. Hence, the current study was conducted to validate the prognostic role of TP53 mutation in MB and to understand its contribution to tumorigenesis.

AB - The role of TP53 mutations in the tumorigenesis of sporadic medulloblastoma (MB) and the value of TP53 mutation status as a prognostic marker are not yet definitely elucidated. A recent report identified TP53 mutations in MB as an adverse prognostic marker. Hence, the current study was conducted to validate the prognostic role of TP53 mutation in MB and to understand its contribution to tumorigenesis.

M3 - SCORING: Zeitschriftenaufsatz

VL - 28

SP - 5188

EP - 5196

JO - J CLIN ONCOL

JF - J CLIN ONCOL

SN - 0732-183X

IS - 35

M1 - 35

ER -